Skip to main content
Quest Diagnostics

Genetic Findings From a Multi-Gene Panel for Hereditary Predisposition to Leukemia

CAGC 2024

Canadian Association of Genetic Counsellors 2024 Annual Education Conference

Quebec City, Canada, Sep 25-28, 2024

Poster presentation: Genetic Findings From a Multi-Gene Panel for Hereditary Predisposition to Leukemia

Authors: Howell V, Scocchia A, Hathaway J, Sluyters A, Gall K, Hirvonen E, Mårtensson E, Niskakoski A, Kokkonen P, Koskinen L, Myllykangas S, Salmenperä P, Koskenvuo J

Specialty: Genetics, Oncology

Disclaimer: One or more of the authors of this abstract were employed at the time by BluePrint Genetics, a subsidiary of Quest Diagnostics.

Related content

On-Demand Webinar
Precision Medicine: Your Role in Advancing the Future of Cancer Care
On-Demand Webinar
Hemepath Master Class Myeloid Neoplasms MPN MDS AML
Audio Podcast
Optimize Oncology Care with Clinical Pathways
Publication
Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation
Publication
A rare case of therapy-related B-cell acute lymphoblastic leukemia arising from acute myeloid leukemia

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.